Brokerages Set Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) PT at $6.50

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) has been assigned an average rating of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $7.00.

A number of equities analysts recently commented on WHWK shares. Oppenheimer started coverage on Whitehawk Therapeutics in a report on Thursday, February 5th. They set an “outperform” rating and a $6.00 target price for the company. Citigroup started coverage on Whitehawk Therapeutics in a report on Thursday. They set an “outperform” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Friday, March 27th. Citizens Jmp started coverage on Whitehawk Therapeutics in a report on Thursday. They set a “market outperform” rating and a $8.00 target price for the company. Finally, JonesTrading started coverage on Whitehawk Therapeutics in a report on Monday, December 22nd. They set a “buy” rating and a $7.00 target price for the company.

More Whitehawk Therapeutics News

Here are the key news stories impacting Whitehawk Therapeutics this week:

• Positive Sentiment: Citizens/JMP initiated coverage with a “Market Outperform” and an $8.00 price target (roughly ~95% above recent levels), a catalyst that has supported buying interest ahead of impending trial data. Citizens Outperform
• Neutral Sentiment: Whitehawk’s CEO will appear in a Jones Trading Post–AACR virtual fireside chat on April 23 — a visibility event that can help inform investors but is unlikely to move the stock by itself. Fireside Chat
• Neutral Sentiment: Institutional ownership is meaningful (~52%) and coverage is mixed: a consensus “Hold” with an average target near $6.50 (some firms bullish, others negative), so analyst views are a mixed influence on price. Institutional Holdings
• Negative Sentiment: Significant insider selling this week — CFO Scott Giacobello sold 141,600 shares (4/16) and 77,000 shares (4/15) and director/officer Bryan Ball sold multiple blocks — has increased supply and likely pressured the stock. Company disclosures say the sales were to cover tax withholding on vested awards, but the size and frequency of sales reduced insiders’ stakes materially. SEC filings: CFO Form 4 and Other Insider Forms

Insider Activity at Whitehawk Therapeutics

In other Whitehawk Therapeutics news, CFO Scott M. Giacobello sold 141,600 shares of the stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $4.13, for a total value of $584,808.00. Following the sale, the chief financial officer owned 295,224 shares of the company’s stock, valued at $1,219,275.12. This trade represents a 32.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Bryan Ball sold 92,460 shares of the stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $3.64, for a total value of $336,554.40. Following the completion of the sale, the insider directly owned 397,106 shares in the company, valued at $1,445,465.84. This represents a 18.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 705,358 shares of company stock worth $2,584,564 in the last three months. 49.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Whitehawk Therapeutics

A number of hedge funds have recently bought and sold shares of WHWK. Avoro Capital Advisors LLC acquired a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth about $5,414,000. Suvretta Capital Management LLC acquired a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth about $7,030,000. Ally Bridge Group NY LLC acquired a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth about $1,554,000. Peapod Lane Capital LLC acquired a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth about $577,000. Finally, ABG Innovation Capital Partners III GP Ltd acquired a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth about $51,000. Institutional investors and hedge funds own 52.08% of the company’s stock.

Whitehawk Therapeutics Stock Performance

NASDAQ WHWK opened at $4.11 on Thursday. The company has a market cap of $193.98 million, a P/E ratio of 8.74 and a beta of 0.57. Whitehawk Therapeutics has a one year low of $1.39 and a one year high of $4.48. The business has a fifty day moving average price of $3.46 and a 200 day moving average price of $2.79.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.21.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.